Eyenovia's Optejet Shows Lower Proinflammatory Cytokines Levels, Chemokines Than Standard Drops

  • Eyenovia Inc EYEN announced results from a research study that evaluated the gene and protein expression of cytokines and chemokines after latanoprost+benzalkonium chloride (BAK) treatment administered via Optejet versus latanoprost+BAK administered via standard eye drops.
  • Preservatives are used to support product sterility and prolong shelf-life. But patients treated with BAK preserved glaucoma medications often suffer inflammatory side effects.
  • Related: HC Wainwright Initiates This Eye-Focused Stock With Almost 400% Upside.
  • The study found that the expression of proinflammatory cytokines and chemokines was decreased in two out of three cytokines with the latanoprost+BAK treatment administered via Optejet technology compared to latanoprost+BAK administered via standard drops. 
  • In these early findings, the Optejet technology appears better than latanoprost+BAK administered via standard drops in reducing inflammatory processes and pathways.
  • Eyenovia's Optejet microdose formulation and delivery platform for ocular therapeutics use high-precision piezo-print technology to deliver 6-8 μL of a drug, consistent with the capacity of the tear film of the eye. 
  • Eyenovia estimates the volume of ophthalmic solution administered with the Optejet is less than 20% of that delivered using conventional eyedroppers, thus reducing overdosing and exposure to drugs and preservatives.
  • Price Action: EYEN shares are up 11.70% at $2.10 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!